Another Biomarker Linked to Risk for Bleeding and Mortality in Patients with AF

However, the biomarker does not carry independent information about stroke compared with other, previously identified cardiac biomarkers.

Atrial fibrillation (AF) is associated with increased risk for stroke and mortality. Physicians use clinical variables to try to estimate risks for stroke, bleeding, and mortality in these patients; more recently, various biomarkers (cardiac troponin I, N-terminal pro-brain natriuretic peptide [NT-proBNP], and cystatin-C) have been explored for their ability to predict outcomes in patients with AF. In a substudy of the industry-funded ARISTOTLE trial, researchers assessed the association between baseline levels of another biomarker — growth differentiation factor 15 (GDF-15), a marker of inflammation and oxidative stress — and clinical outcomes in 14,798 patients with AF.

GDF-15 levels correlated with levels of the three previously identifie…

Reviewing Author

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

Another Biomarker Linked to Risk for Bleeding and Mortality in Patients with AF

Topics

Reviewing Author